# Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

> **NCT04377620** · PHASE3 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 211 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04377620
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-24
- **Primary completion:** 2021-02-26
- **Final completion:** 2021-02-26
- **Target enrollment:** 211 (ACTUAL)
- **Why stopped:** Study terminated by sponsor
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04377620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04377620, "Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04377620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*